HONG KONG, Feb. 22, 2011 /PRNewswire/ — OrbusNeich today
announced that 12-month follow-up data from the e-HEALING
(Healthy Endothelial Accelerated Lining
Inhibits Neointimal Growth) registry published
in the February issue of EuroIntervention
demonstrated good clinical outcomes with low incidence of
repeat revascularization and stent thrombosis (ST) for the
company’s Genous Stent.
Target vessel failure (TVF), defined as target vessel-related
cardiac death or myocardial infarction (MI) and target vessel
revascularization (TVR), was 8.4 percent at 12 months. The
composite of death, MI or target lesion revascularization (TLR)
occurred in 7.9 percent of the patients. TLR and ST were 5.7
percent and 1.1 percent, respectively.
“The good clinical outcomes for the Genous Stent in real-world
use, especially the low incidence of stent thrombosis, demonstrate
that the pro-healing approach of the Genous Stent is effective for
a range of challenging patient groups,” said Professor Sigmund
Silber, M.D., Ph.D., of the Kardiologische Klinik Dr Muller,
Munich, co-principal investigator and one of the lead authors of
the publication. “As shown previously in several subset analyses of
the e-HEALING registry, the Genous Stent produces exceptional
outcomes in diabetic and elderly patients.”
e-HEALING, a multi-center, worldwide prospective clinical
registry conducted in 31 countries outside of the United States at
144 centers, included 4,939 patients with at least one lesion
suitable for non-urgent percutaneous coronary intervention (PCI)
and Genous Stent implantation. The mean age of the study population
was 63 years, and 79 percent of patients were male. In addition, 25
percent of patients in the study cohort had diabetes mellitus, and
37 percent had a prior MI. On average, 1.3 lesions per patient were
treated – 97.7 percent were de
‘/>”/>
